For decades, the treatment landscape of small-cell lung cancer (SCLC) has been dominated by chemotherapy or chemoradiotherapy. In 2018, Bristol-Myers Squibb’s Opdivo became the first immune checkpoint inhibitor to be approved in the United States for extensive-stage SCLC. 2019 witnessed approvals of two other immune checkpoint inhibitors; Merck & Co.’s Keytruda was approved in the same setting as Opdivo in the United States and Roche / Genentech / Chugai’s Tecentriq was approved in combination with chemotherapy as first-line treatment for extensive-stage SCLC in the seven major markets. Although a novel chemotherapy agent, PharmaMar’s lurbinectedin, was also filed for FDA approval in December 2019, a significant unmet need remains for more therapeutic options. Despite the comparatively small market size, the modest late-phase pipeline looks set to further revolutionize SCLC treatment algorithms, with numerous immune checkpoint inhibitors—such as AstraZeneca’s Imfinzi—anticipated to gain approval and further label expansions across a variety of settings over the SCLC market forecast period.

Questions Answered

  • How is SCLC managed, and how will the treatment paradigm evolve?
  • What are the sizes of the drug-treatable SCLC populations and how will drug-treatment rates change over time?
  • How will the recent approvals of immune checkpoint inhibitors for extensive-stage SCLC impact the market?
  • What are the major unmet needs, and how will key emerging therapies shape the SCLC market over the ten-year forecast period?

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with experts and 210 country-specific surveys of medical oncologists treating SCLC.

Epidemiology: Diagnosed incidence of SCLC by country (segmented by limited-stage and extensive-stage disease).

Population segments in market forecast: Limited-stage, first-line extensive stage, second line, and third line.

Emerging therapies: Phase I/II: 11 drugs; Phase III: 6 drugs.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Findings
      • SCLC - Key Findings
    • Key Updates
      • July 2020
      • May 2020
      • March 2020
    • Market Outlook
      • Key Findings
      • COVID-19: Areas of Potential Forecast Impact
        • COVID-19: Areas of Potential Forecast Impact
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Small-Cell Lung Cancer?
        • What Factors Are Constraining the Market for Small-Cell Lung Cancer?
      • Segment-Specific Trends
        • Limited-Stage, First-Line
        • Extensive-Stage, First-Line
        • Second- and Third-Line
    • Forecast
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
        • Etiology of Small-Cell Lung Cancer
      • Pathophysiology
        • Disease Characteristics
      • Clinical Staging and Risk-Classification
      • Signs and Symptoms
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
        • Key Updates
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution of Small-Cell Lung Cancer
        • Recurrent Incident Cases of Small-Cell Lung Cancer
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Immune Checkpoint Inhibitors
        • Cytotoxic Agents
      • Medical Practice
        • Limited-Stage Small-Cell Lung Cancer
        • First-Line Extensive-Stage Small-Cell Lung Cancer
        • Second-Line Small-Cell Lung Cancer
        • Third-Line Small-Cell Lung Cancer
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Small-Cell Lung Cancer
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Immune Checkpoint Inhibitors
        • Immunomodulatory Agents
        • CDK4/6 Inhibitor
        • Cytotoxic Agents
      • Early-Phase Pipeline Analysis
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Small-Cell Lung Cancer Bibliography

Author(s): Sudha Malhotra, Ph.D; Atul Sharma, MPH; Sorcha Cassidy M.Res., Ph.D

Sudha Malhotra joined Decision Resource Group in 2018. She is responsible for performing secondary market analysis including patent research, pricing, and clinical trial assessment for major pharmaceutical markets covering a wide range of oncology indications. She obtained her doctorate degree in life sciences from the National Institute of Immunology, New Delhi, India and has authored several original peer-reviewed journal articles. She holds a bachelor’s degree in microbiology and a master’s degree in biomedical sciences both from the University of Delhi, India.

Atul Sharma started working in Decision Resources Group as an intern in early 2016 and currently works as an associate epidemiologist. He performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. He produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets. He holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from MN DAV Dental College & Hospital.

Sorcha Cassidy , is an Associate Director in the Oncology team at Decision Resources ; Dr. Cassidy manages a team of analysts who conduct extensive primary and secondary market research on several Oncology indications across the major pharmaceutical markets. She also provides sales and client support across all oncology products. She has in-depth expertise in competitive intelligence, secondary and primary market research, and delivering strategic insights that address key client business questions. Dr. Cassidy holds an and in Immunology from Imperial College London where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIR) on natural killer (NK) cells in various diseases and published several peer-reviewed papers. Prior to joining the company, Dr. Cassidy previously worked as a Market Research Manager in Janssen UK and has extensive experience working across multiple Oncology indications at GlobalData and FirstWord Pharma.

Related Reports

Small Cell Lung Cancer | Epidemiology | Mature Markets

DRG Epidemiology’s coverage of small-cell lung cancer (SCLC) comprises epidemiological estimates of...

View Details